Slingshot members are tracking this event:

Celldex (CLDX) Presents Phase 2 Data Evaluating Glembatumumab Vedotin in Metastatic Melanoma

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Data is expected to be presented at an appropriate medical meeting in the second half of 2016 for a Phase 2 study of glembatumumab vedotin in metastatic melanoma.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 09, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Glembatumumab Vedotin, Metastatic Melanoma, Gpnmb